Low Leverage / Strong Balance SheetNear-zero debt materially reduces interest burden and financial distress risk, giving management durable flexibility to fund R&D, scale manufacturing, or pursue partnerships without immediate refinancing pressure. This structural balance-sheet strength supports multi-quarter operations and strategic options.

Focused Veterinary Vaccine NicheA clear, specialized focus on livestock bacterial vaccines creates durable competitive advantages: regulatory knowhow, distribution relationships with vets/farms, and recurring demand tied to animal health and productivity. This niche can sustain steady product volumes over many quarters.

Demonstrated Ability To Grow Revenue EpisodicallyPeriodic sharp revenue increases indicate the company can secure commercial uptake and scale sales when product launches or orders align. That capability suggests an addressable market and distribution execution that, if stabilized, could translate into durable top-line growth over multiple quarters.

Bears Say

Persistent Negative Cash FlowConsistent operating and free cash outflows imply the business cannot self-fund its operations or growth, forcing reliance on external financing. Over 2-6 months this limits capital for commercialization, increases dilution risk, and constrains investment in manufacturing or market expansion.

Sustained Operating Losses And Margin DeteriorationDeep, persistent losses and a recent gross loss despite rising revenue point to structural cost or pricing issues. If product economics are weak, margins may remain pressured, making it harder to reach break-even and sustain long-term commercialization without business model adjustments.

Equity Erosion RiskDeclining equity reduces the cushion against future losses and raises the probability of needing dilutive capital injections. Over the medium term this can limit strategic flexibility, increase shareholder dilution risk, and weaken the balance-sheet safety net despite low debt.

IVACC FAQ

What was Intervacc AB’s price range in the past 12 months?

Intervacc AB lowest stock price was kr0.69 and its highest was kr1.35 in the past 12 months.

What is Intervacc AB’s market cap?

Intervacc AB’s market cap is kr295.83M.

When is Intervacc AB’s upcoming earnings report date?

Intervacc AB’s upcoming earnings report date is May 13, 2026 which is in 83 days.

How were Intervacc AB’s earnings last quarter?

Intervacc AB released its earnings results on Feb 17, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.06 by -kr0.04.

Is Intervacc AB overvalued?

According to Wall Street analysts Intervacc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intervacc AB pay dividends?

Intervacc AB does not currently pay dividends.

What is Intervacc AB’s EPS estimate?

Intervacc AB’s EPS estimate is -0.06.

How many shares outstanding does Intervacc AB have?

Intervacc AB has 340,813,200 shares outstanding.

What happened to Intervacc AB’s price movement after its last earnings report?

Intervacc AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.06. Following the earnings report the stock price went down -16.471%.

Which hedge fund is a major shareholder of Intervacc AB?

Currently, no hedge funds are holding shares in SE:IVACC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.